Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Key Takeaways Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness platform missed analysts' estimates for current-quarter sales on the impact of ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Novo Nordisk, the maker of Wegovy, announced exclusively on " Good Morning America " Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...